Transcription of Anticoagulation with Warfarin - PCICS
{{id}} {{{paragraph}}}
Anticoagulation with Warfarin Loren Brown, BSN, RN, CCRN Clinical Nursing Educator, Cardiovascular Catheterization Lab Children s Hospital Boston Boston, Massachusetts Introduction: Many adults with congenital heart defects need to take anticoagulants. Common reasons for this type of treatment include prosthetic heart valve replacements, atrial arrhythmias, previous surgeries such as the Fontan operation, or other diagnoses where blood flow is turbulent due to narrow vessels, aneurysms, poor ejection or artificial devices. Anticoagulants slow blood clotting, preventing complications like blood clots forming on artificial valves, valve obstruction and blood clots traveling to the brain causing a stroke. Lesions: (Monagle, 2004, 2008) Indications/Goal Ranges Indication INR Goal Range DVT/PE 2-3 Prosthetic heart valves Aortic position 2-3 Prosthetic heart valves Mitral position Fontan Pulmonary Hypertension DVT Prophylaxis Cardiomyopathy 2-3 Kawasaki Disease 2-3 Atrial Fibrillation 2-3 Critical Thinking Points: Initial Response is usually with 24 hours after administration Peak Anticoagulation response 72 to 96 hr Duration of action of a single dose is 2-5 days Half life: Following a single Warfarin dose, the terminal h
Anticoagulation with Warfarin Loren Brown, BSN, RN, CCRN Clinical Nursing Educator, Cardiovascular Catheterization Lab Children’s Hospital Boston
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Anticoagulation, Pediatric Cardiology, Pediatric, Anticoagulation in pediatric cardiac disease, St. Vincent Outpatient Medication Management Services, Cardiology, Therapeutic Dosing of Unfractionated Heparin, Therapeutic Dosing of Unfractionated Heparin – Pediatric – Inpatient – Clinical, Paediatric Thrombosis and Anticoagulation, PRACTICE GUIDELINES FOR ANTICOAGULATION, PRACTICE GUIDELINES FOR ANTICOAGULATION MANAGEMENT, Pediatric CRRT The Basics, Guidelines for antithrombotic therapy